SCHEMBL499184

SCHEMBL499184

O=C1OC2(c3cc(I)c(O)cc3Oc3cc(O)c(I)cc32)c2ccccc21

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.64
MEN1 O00255 5/20 0.64
KMT2A Q03164 5/20 0.64
TDP1 Q9NUW8 4/20 0.64
FTO Q9C0B1 3/20 0.64
RECQL P46063 2/20 0.64
BLM P54132 2/20 0.64
ACE2 Q9BYF1 2/20 0.64
HTT P42858 2/20 0.64
PRMT1 Q99873 2/20 0.64
CYP2C19 P33261 2/20 0.64
HPGD P15428 1/20 0.64
SMAD3 P84022 1/20 0.64
USP2 O75604 2/20 0.62
L3MBTL1 Q9Y468 2/20 0.62
THRB P10828 1/20 0.62
CDK2 P24941 1/20 0.62
CHAT P28329 1/20 0.62
BLVRB P30043 1/20 0.62
RXFP1 Q9HBX9 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32672781 0.88 MAPT (0.62) MAPTMEN1KMT2ATDP1FTO
SCHEMBL31620935 0.88 MAPT (0.71) MAPTMEN1KMT2ATDP1FTO
SCHEMBL9307936 0.88 MEN1 (0.80) MAPTMEN1KMT2ATDP1FTO
SCHEMBL30160703 0.88 MEN1 (0.80) MAPTMEN1KMT2ATDP1FTO
SCHEMBL5364186 0.88 MEN1 (0.62) MAPTMEN1KMT2ATDP1FTO
Dichlorofluorescein SCHEMBL30606648 0.83 MAPT (0.64) MAPTMEN1KMT2ATDP1FTO
Dichlorofluorescein SCHEMBL29364373 0.83 MAPT (0.64) MAPTMEN1KMT2ATDP1FTO
SCHEMBL408340 0.83 MAPT (0.64) MAPTMEN1KMT2ATDP1FTO
SCHEMBL499135 0.83 MAPT (0.64) MAPTMEN1KMT2ATDP1FTO
SCHEMBL30599806 0.83 MAPT (0.64) MAPTMEN1KMT2ATDP1FTO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023192788-A1 DEVELOPER COMPOSITION COMPRISING DIRECT DYE L'OREAL (FR) 2023-10-05 WO claimed
US-20230310285-A1 DEVELOPER COMPOSITION COMPRISING DIRECT DYE L'OREAL (FR) 2023-10-05 US claimed
US-11975221-B2 Anti-microbial multilayer fabric media and method for making same Shuai Danmeng (US) 2024-05-07 US disclosed
US-20240041739-A1 BIOPHOTONIC COMPOSITIONS AND METHODS FOR PROVIDING BIOPHOTONIC TREATMENT KLOX TECHNOLOGIES INC. (CA) 2024-02-08 US disclosed
EP-4274443-A1 ANTI-MICROBIAL MULTILAYER FABRIC MEDIA AND METHOD FOR MAKING SAME Shuai, Danmeng (US) 2023-11-15 EP disclosed
WO-2023192788-A1 DEVELOPER COMPOSITION COMPRISING DIRECT DYE L'OREAL (FR) 2023-10-05 WO disclosed
US-20230310285-A1 DEVELOPER COMPOSITION COMPRISING DIRECT DYE L'OREAL (FR) 2023-10-05 US disclosed
US-11723854-B2 Biophotonic compositions and methods for providing biophotonic treatment FLE INTERNATIONAL S.R.L. (IT) 2023-08-15 US disclosed
US-20220387592-A1 BIOPHOTONIC COMPOSITIONS AND METHODS FOR PROVIDING BIOPHOTONIC TREATMENT FLE INTERNATIONAL S.R.L. (IT) 2022-12-08 US disclosed
WO-2022155672-A1 ANTI-MICROBIAL MULTILAYER FABRIC MEDIA AND METHOD FOR MAKING SAME Shuai Danmeng (US) 2022-07-21 WO disclosed
US-20220219027-A1 ANTI-MICROBIAL MULTILAYER FABRIC MEDIA AND METHOD FOR MAKING SAME Shuai Danmeng (US) 2022-07-14 US disclosed
WO-2002062386-A2 PHOTODYNAMIC THERAPY OF OCCULT CHOROIDAL NEOVASCULARIZATION LINKED TO AGE-RELATED MACULAR DEGENERATION QLT INC. (CA) 2002-08-15 WO disclosed
WO-2002062384-A2 REDUCED FLUENCE RATE PDT QLT INC. (CA) 2002-08-15 WO disclosed
EP-1229937-A2 USE OF PDT TO INHIBIT INTIMAL HYPERPLASIA QLT Inc. (CA) 2002-08-14 EP disclosed
US-20020061330-A1 Supports for photosensitizer formulations BRITISH COLUMBIA, THE UNIVERSITY OF (CA) 2002-05-23 US disclosed
US-20020022032-A1 Immuno-adjuvant PDT treatment of metastatic tumors QLT INC. (CA) 2002-02-21 US disclosed
WO-2001085212-A2 DRUG DELIVERY SYSTEMS FOR PHOTODYNAMIC THERAPY THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2001-11-15 WO disclosed
US-6284365-B1 FOR CONTROLLING PHYSICAL PROPERTIES OF SURFACE AND INTERFACE OF SOLID ARTICLE SUCH AS WETTABILITY, ADHESIVE PROPERTY, SURFACE ENERGY, DISPERSABILITY, CHEMICAL RESISTANCE FUJI XEROX CO., LTD. (JP) 2001-09-04 US disclosed
WO-2001035996-A2 USE OF PDT TO INHIBIT INTIMAL HYPERPLASIA QLT INC. (CA) 2001-05-25 WO disclosed
WO-2001035997-A2 USE OF LOW-DOSE PDT TO INHIBIT RESTENOSIS QLT INC. (CA) 2001-05-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020061330-A1 Supports for photosensitizer formulations PPOX, PPIF, SDHA MAPT 1710/4885MEN1 2343/4885KMT2A 2286/4885
US-20020022032-A1 Immuno-adjuvant PDT treatment of metastatic tumors CD74, ANXA11, ANXA1 MAPT 1243/4885MEN1 2685/4885KMT2A 2520/4885
US-20230310285-A1 DEVELOPER COMPOSITION COMPRISING DIRECT DYE TYR, CYB5R3, POLR1C MAPT 3307/4885MEN1 2132/4885KMT2A 1128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.